Other languages Vigil Neuroscience, Inc.

Equities

VIGL

US92673K1088

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-28 pm EDT			5-day change	1st Jan Change
3.31 ^USD	-8.82%		-5.43%	-2.07%

May. 07	Vigil Neuroscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 17	Vigil Neuroscience, Inc. Presents Key Findings from Illuminate & Ignite Studies in ALSP At the 2024 American Academy of Neurology Annual Meeting	CI

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Vigil Neuroscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07
Vigil Neuroscience, Inc. Presents Key Findings from Illuminate & Ignite Studies in ALSP At the 2024 American Academy of Neurology Annual Meeting	Apr. 17
Vigil Neuroscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26
Vigil Neuroscience, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 26
Vigil Neuroscience Names Petra Kaufmann Chief Medical Officer	Mar. 20
Vigil Neuroscience, Inc. Announces Executive Changes	Mar. 20
Vigil Neuroscience Reports Positive Interm Results for Treatment of Axonal Spheroids and Pigmented Glia	Nov. 16
Vigil Neuroscience, Inc. Reports Positive Interim Data from Phase 2 Ignite Proof-Of-Concept Clinical Trial Evaluating Iluzanebart as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATE	Nov. 16
Vigil Neuroscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07
Vigil Neuroscience Shares Rise After First Participant Dosed in Phase 1 Trial of Potential Alzheimer's Disease Treatment	23-10-17
Vigil Neuroscience, Inc. Announces First Participant Dosed in Phase 1 Clinical Trial in Healthy Volunteers Evaluating Vv-3927, a Small Molecule Trem2 Agonist, for Potential Treatment of Alzheimer's Disease	23-10-17
Vigil Neuroscience, Inc Provides an Update on the Small Molecule TREM2 Agonist, VG-3927	23-10-12
Vigil Says Orphan Drug Designation Application for Proposed Leukoencephalopathy Therapy Secured European Positive Opinion	23-09-26
Vigil Neuroscience, Inc. Receives Positive Opinion from European Medicines Agency on Orphan Drug Designation for Vgl101 for the Treatment of ALSP	23-09-26
Vigil Neuroscience's VGL101 Healthy Volunteer Trial Shows Favorable Safety, Tolerability Profile	23-09-11
Vigil Neuroscience, Inc. Presents VGL101 Complete Phase 1 Data and Phase 2 Ignite Trial Design at the 2023 American Neurological Association Annual Meeting	23-09-11
Ververv Neuroscience, Inc. Receives Notification from the U.S. Food and Drug Administration Regarding Its Investigational New Drug Application to Evaluate the Company's Oral Small Molecule Trem2 Agonist Vv-3927	23-09-08
Vigil Neuroscience, Inc. Appoints Christopher J. Silber, M.D. as Chief Medical Officer	23-08-08
Vigil Neuroscience, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08
Vigil Neuroscience Names Christopher Silber Chief Medical Officer	23-08-08

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Vigil Neuroscience, Inc.

Equities

VIGL

US92673K1088

Other languages

Filters